These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients. Avouac J; Miceli-Richard C; Combier A; Steelandt A; Fogel O; Mariaggi AA; Meritet JF; Rozenberg F; Molto A; Allanore Y Rheumatology (Oxford); 2022 Jun; 61(SI2):SI163-SI168. PubMed ID: 34726701 [TBL] [Abstract][Full Text] [Related]
6. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2. Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039 [TBL] [Abstract][Full Text] [Related]
7. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. Fabris M; De Marchi G; Domenis R; Caponnetto F; Guella S; Dal Secco C; Cabas N; De Vita S; Beltrami AP; Curcio F; Quartuccio L J Autoimmun; 2022 May; 129():102827. PubMed ID: 35427999 [TBL] [Abstract][Full Text] [Related]
8. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients. Asplund Högelin K; Ruffin N; Pin E; Hober S; Nilsson P; Starvaggi Cucuzza C; Khademi M; Olsson T; Piehl F; Al Nimer F Eur J Neurol; 2022 Nov; 29(11):3317-3328. PubMed ID: 35808856 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters. Magliulo D; Wade SD; Kyttaris VC Clin Immunol; 2022 Jan; 234():108897. PubMed ID: 34848357 [TBL] [Abstract][Full Text] [Related]
10. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX). Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048 [TBL] [Abstract][Full Text] [Related]
12. Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2 in patients with rheumatic pathology under biological treatment. Flores-Fernández E; Vázquez-Gomez I; Valls-Pascual E; Valera-Ribera C; Andújar-Brazal P; Alegre-Sancho JJ Reumatol Clin (Engl Ed); 2023 Dec; 19(10):565-570. PubMed ID: 38008603 [TBL] [Abstract][Full Text] [Related]
13. Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases. Troldborg A; Thomsen MK; Bartels LE; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Mikkelsen S; Erikstrup C; Hauge EM; Ammitzbøll C J Rheumatol; 2022 Jun; 49(6):644-649. PubMed ID: 35232803 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma. Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299 [TBL] [Abstract][Full Text] [Related]
15. B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab. Schultz K; Jannat-Khah D; Spiera R J Rheumatol; 2023 Mar; 50(3):420-425. PubMed ID: 36521910 [TBL] [Abstract][Full Text] [Related]
16. Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases. Bitoun S; Henry J; Desjardins D; Vauloup-Fellous C; Dib N; Belkhir R; Mouna L; Joly C; Bitu M; Ly B; Pascaud J; Seror R; Roque Afonso AM; Le Grand R; Mariette X Arthritis Rheumatol; 2022 Jun; 74(6):927-933. PubMed ID: 34962357 [TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour. Ammitzbøll C; Thomsen MK; Andersen JB; Bartels LE; Hermansen MF; Johannsen AD; Mistegaard CE; Mikkelsen S; Vils SR; Erikstrup C; Hauge EM; Troldborg A Mod Rheumatol; 2023 Jul; 33(4):777-785. PubMed ID: 35860843 [TBL] [Abstract][Full Text] [Related]